CN101952314B - 快速清除多肽的生物动力学 - Google Patents

快速清除多肽的生物动力学 Download PDF

Info

Publication number
CN101952314B
CN101952314B CN200880127378.0A CN200880127378A CN101952314B CN 101952314 B CN101952314 B CN 101952314B CN 200880127378 A CN200880127378 A CN 200880127378A CN 101952314 B CN101952314 B CN 101952314B
Authority
CN
China
Prior art keywords
polypeptide
amino acid
affibodies
target
isoelectric point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880127378.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101952314A (zh
Inventor
C·伦德尔
E·贡内里乌松
M·林德博里
B·D-L·李
J·W·卡斯特尔
F·A·休德
M·E·马里诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Precision Healthcare LLC
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Co filed Critical General Electric Co
Publication of CN101952314A publication Critical patent/CN101952314A/zh
Application granted granted Critical
Publication of CN101952314B publication Critical patent/CN101952314B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CN200880127378.0A 2007-12-19 2008-12-17 快速清除多肽的生物动力学 Active CN101952314B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/002972 2007-12-19
US12/002,972 US8937047B2 (en) 2007-12-19 2007-12-19 Biokinetics of fast-clearing polypeptides
PCT/EP2008/067774 WO2009077569A1 (en) 2007-12-19 2008-12-17 Biokinetics of fast-clearing polypeptides

Publications (2)

Publication Number Publication Date
CN101952314A CN101952314A (zh) 2011-01-19
CN101952314B true CN101952314B (zh) 2016-04-20

Family

ID=40591871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880127378.0A Active CN101952314B (zh) 2007-12-19 2008-12-17 快速清除多肽的生物动力学

Country Status (7)

Country Link
US (1) US8937047B2 (cg-RX-API-DMAC7.html)
EP (1) EP2231706B3 (cg-RX-API-DMAC7.html)
JP (1) JP5745275B2 (cg-RX-API-DMAC7.html)
CN (1) CN101952314B (cg-RX-API-DMAC7.html)
AT (1) ATE529445T1 (cg-RX-API-DMAC7.html)
ES (1) ES2375018T7 (cg-RX-API-DMAC7.html)
WO (1) WO2009077569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
EP2077272A1 (en) * 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
US10861978B2 (en) 2012-04-02 2020-12-08 Samsung Display Co., Ltd. Display device
CN112870390B (zh) * 2021-01-29 2022-04-22 四川大学华西医院 一种镓68标记的亲合体蛋白pet显像剂及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329185A2 (en) * 1988-02-17 1989-08-23 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US20020052488A1 (en) * 1996-07-19 2002-05-02 Amgen Inc. Substitution analogs of NT-3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US6020163A (en) 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329185A2 (en) * 1988-02-17 1989-08-23 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US20020052488A1 (en) * 1996-07-19 2002-05-02 Amgen Inc. Substitution analogs of NT-3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Burczynski F. J. et al..Hepatocyte [3H]-palmitate uptake: effect of albumin surface charge modification.《Can. J. Physiol. Pharmacol.》.2001,第79卷第869-871页. *
Hepatocyte [3H]-palmitate uptake: effect of albumin surface charge modification;Burczynski F. J. et al.;《Can. J. Physiol. Pharmacol.》;20011003;第79卷;第869-871页 *

Also Published As

Publication number Publication date
EP2231706B1 (en) 2011-10-19
WO2009077569A1 (en) 2009-06-25
ES2375018T3 (es) 2012-02-24
ES2375018T7 (es) 2013-02-13
US8937047B2 (en) 2015-01-20
JP2011509926A (ja) 2011-03-31
US20090180954A1 (en) 2009-07-16
JP5745275B2 (ja) 2015-07-08
EP2231706B3 (en) 2012-07-18
ATE529445T1 (de) 2011-11-15
EP2231706A1 (en) 2010-09-29
CN101952314A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
EP2231706B3 (en) Biokinetics of fast-clearing polypeptides
US8124725B2 (en) PDGF-Rβ binders
Feldwisch et al. Engineering of affibody molecules for therapy and diagnostics
Wu et al. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.
JP5986095B2 (ja) コンジュゲートおよび分子イメージングにおけるそれらの用途
US9989524B2 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
US20180250426A1 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
CN111228521A (zh) 一种Dar2多肽放射性药物及其制备方法
Long et al. Trends in nanobody radiotheranostics
US11242359B2 (en) Biocompatible modular tetrazine platform
CA2614486C (en) Contrast agent comprising a scaffold protein and a metal ion chelating site integrated therein
N’Guessan et al. Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering
ES2657053T3 (es) Agente de formación de inmunoimágenes para el uso con la terapia de conjugado de anticuerpo-fármaco
US9844607B2 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
Pietzsch et al. Single Photon Emission Computed Tomography Tracer
WO2019175019A1 (en) Compounds and methods for detecting early atherosclerotic lesions in blood vessels
TW202530249A (zh) 小蛋白、結合物及其用途
WO2025212955A1 (en) Method for diagnosing amyloid diseases
JP2026515172A (ja) Alsバイオマーカーのインビボ画像化およびそのための手段
JP2023554258A (ja) 新規のポリペプチド
Cook The Development of Novel Platforms for the Imaging of Cancer by Positron Emission Tomography
Lee Investigating protein surfaces and protein interactions using the element-coded affinity tags (ECAT)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20260430

Address after: Wisconsin

Patentee after: Ge precision medical Co.,Ltd.

Country or region after: U.S.A.

Address before: New York State, USA

Patentee before: General Electric Co.

Country or region before: U.S.A.

TR01 Transfer of patent right